Orient Pharma (OP), a reinvested subsidiary of the Orient EuroPharma Group (OEP), will be listed on Taiwan's over-the-counter (OTC) market in late August 2025. Ahead of the listing, OP and OEP chairman Peter Tsai points to the knowledge and professionalism...
The article requires paid subscription. Subscribe Now